MENU
+Compare
CANC
ETF ticker: NASDAQ
AS OF
Sep 26, 02:22 PM (EDT)
Price
$27.04
Change
+$0.29 (+1.08%)
Net Assets
74.27M

CANC stock forecast, quote, news & analysis

The investment seeks to provide long-term growth... Show more

Category: #Health
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for CANC with price predictions
Sep 25, 2025

Momentum Indicator for CANC turns negative, indicating new downward trend

CANC saw its Momentum Indicator move below the 0 level on September 25, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator turned negative. In of the 32 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CANC moved out of overbought territory on September 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 7 similar instances where the indicator moved out of overbought territory. In of the 7 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for CANC turned negative on September 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 18 similar instances when the indicator turned negative. In of the 18 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in of 132 cases, the price rose further within the following month. The odds of a continued upward trend are .

CANC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 83 cases where CANC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Illumina (NASDAQ:ILMN).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF ETF is 41.72B. The market cap for tickers in the group ranges from 3.51M to 640.6B. LLY holds the highest valuation in this group at 640.6B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF ETF was 30%. For the same ETF, the average monthly price growth was 54%, and the average quarterly price growth was 395%. REPL experienced the highest price growth at 17%, while JANX experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF ETF was -12%. For the same stocks of the ETF, the average monthly volume growth was 21% and the average quarterly volume growth was 50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 79
Price Growth Rating: 56
SMR Rating: 78
Profit Risk Rating: 81
Seasonality Score: -29 (-100 ... +100)
View a ticker or compare two or three
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co